SumáRIo

A radiocirurgia se tornou uma importante alternativa à cirurgia para o tratamento de diversas lesões intracranianas. Na prática médica atual, a radiocirurgia substituiu a cirurgia como terapia de escolha em algumas situações, complementa a cirurgia como tratamento adjuvante pós-operatório em outras; e mais comumente é uma alternativa à cirurgia ou representa a única alternativa terapêutica. As técnicas radiocirúrgicas têm evoluido rapidamente com o desenvolvimento de novas tecnologias permitindo planos de tratamento mais complexos e eficientes. Como consequência, estas tecnologias têm ampliado as aplicações da radiocirurgia e melhorado seus resultados. Entre estas novas técnicas, o tratamento envolvendo radiação estereotáxica fracionada, denominado de radioterapia esterotáxica fracionada (FSR) surgiu como consequência dos aceleradores lineares projetados e dedicados a técnicas estereotáxicas. Sem as limitações logísticas da utilização de aceleradores lineares de uso geral em radioterapia, usualmente disponíveis somente uma ou duas vezes por semana, as unidades dedicadas permitiram o desenvolvimento de paradigmas de tratamento buscando um tratamento ideal baseado na radiobiologia do alvo e nas limitações de dose dos tecidos circunvizinhos. Este capítulo irá sumarizar nossa experiência de 15 anos utilizando inicialmente o sistema Varian 600SR associado ao software Radionics, e mais recentemente o sistema Novalis capaz de realizar radiocirurgia com feixes modulados, descrevendo assim nossa prática com FSR para uma variedade de lesões intracranianas. Atenção especial será dada a tumores próximos ou envolvendo nervos cranianos sensitivos especiais. Dada a versatilidade do sistema Novalis, existe a opção de comparação de diferentes formas de planejamento de tratamento de uma única vez, incluindo radioterapia com intensidade modulada estereotáxica (IMRT). Para lesões selecionadas da base do crânio, nós acreditamos que a IMRT estereotáxica proporciona uma conformalidade maior que a FSR e com isto, iremos incluir esta aplicação
ABSTRACT
BaCkground
Optic nerve sheath meningiomas represent one-third of all optic nerve tumors, but are comparatively rare among meningiomas 16 . These tumors can arise intraorbitally from arachnoid cap cells within the fibrous dural capsule of the optic nerve. Alternatively, they may represent secondary extensions from an intracranial site 1, 27 . ONSM typically exhibit a meningotheliomatous or transitional histology and are classified as benign under the World Health Organization (Helsinki) grading system for meningiomas 18, 26 . A salient symptom is early visual loss, presumably from a combination of compression and circulatory interference of the optic nerve as the tumor enlarges within the dural sheath. Common signs include optic atrophy and optociliary shunt vessels 22, 5 . While long-term survival is likely, the vast majority of untreated patients will progress to complete blindness in the affected eye 14 .
Patients with useful vision and no documented tumor growth have traditionally been observed while surgery has been reserved for patients with progressive symptoms or evidence of tumor growth 10 . Due to their intimate circumferential relationship to the optic nerve and central retinal artery ONSM have historically been extremely difficult to resect surgically even with modern microneurosurgical techniques.
The role of radiation therapy in optic nerve sheath meningiomas remains controversial and largely unexplored with few published reports to date. Arguments against this modality include frequent lack of radiographic response to radiation and potential postradiation injury of the optic nerve 6, 23 and uninvolved optic apparatus. However, recent reports in the literature have demonstrated the potential efficacy of radiation therapy in preserving or improving vision 8, 12, 14, 15, 21 . Indeed, several authors have suggested radiation therapy as an adjuvant therapy for incompletely resected tumors 3, 4 or as the primary management of ONSM.
CuRRENT LITERATuRE
Table one summarizes the current experience with focused radiation techniques for treatment of ONSM. 
1.8 Gy/ 50.4 Gy + 2 x 3.6 Gy boost 
3-D conformal radiation
N a = eyes with measureable function before treatment; b = only 9/14 had baseline visual fields and 9/9 had improvement ▲ = improvement in function; ► = no change in function; ▼ = loss of function Three publications have compared FSR outcomes to non-radiation management including either observation, surgery, or surgery followed by observation. Outcomes from 2 publications including are own are featured in Table 2 below. Neither surgery nor observation yields any likelihood of visual improvement whereas, based on published literature, FSR yields visual improvements ranging from 25-80% for visual fields and 8-86% for refracted visual acuity (Table 1) . With FSR, the combined likelihood of improvement or stabilization climbs to a range of 92-100% for visual fields and 86-100% for visual acuity. In a more detailed follow-up ophthalmologic analysis of outcomes in a subset of these patients, we have noted improvements in not only visual fields ( Figure 5 ) but also refracted visual acuity and color perception 6 .
These rates compare favorably to considerably lower vision preservation rates after surgery or observation (Table 2) . When compared to observation or surgery, visual outcomes were significantly better and we concluded that patients with ONSM should be treated upfront solely on radiographic diagnostic criteria 2 .
These data are further supported by the analysis of Turbin et. al 25 . These authors retrospectively compared the outcomes of 64 patients with diagnosed ONSM treated with either obser- vation, surgery, radiotherapy, or a combination of surgery and radiotherapy. Of 59 patients with vision greater than light perception at diagnosis, 13 patients were observed only, 12 had surgery only, 18 received radiation alone, and 16 had surgery and radiation. Irradiated patients received between 40 and 55 Gy of conventional multiport or conformal external beam radiation. Ratio acuity scores revealed that visual acuity fell significantly for observed only, surgery only, and surgery with radiation groups, whereas the radiation only group manifested a decrease in visual acuity that was not significant. 
Landert, 2005 13 (3) a = only visual acuity data available.
RAdIoBIoLogICAL pRINCIpLES oF FSR FoR opTIC NERvE ShEATh mENINgIomA
Fractionated radiotherapy has been used to treat patients with skull base tumors over the last half-century. Stereotactic radiosurgery has made the treatment of skull base tumors far more precise with modern imaging and versatile 3-dimensional treatment planning software which, through dose volume histograms maximizes dose to target with high conformality and minimizes dose to contiguous normal structures. Two exceptions are optic nerve sheath meningiomas and acoustic neuromas where these cranial nerves are intrinsic to the target volume. As special sensory cranial nerves, injury to sensory function occurs much more frequently than either sensory or motor function in mixed cranial nerves, reflecting a lower threshold for injury. Low daily doses of radiation and a cumulative dose below a threshold value, however, have proven to be safe for the optic nerves and more recently for the cochlear nerve. We will advance arguments based on published data that tumors involving or near special sensory cranial nerves, when treatment is indicated, should be treated with FSR utilizing daily conventional fraction sizes.
Single doses of 15 Gy or 54 Gy in 30 daily fractions both result in excellent control of meningiomas 23 . The SRS dose of 15 Gy, however, exceeds the generally accepted single-dose tolerance of the optic nerves (8-10 Gy) for treatment of optic nerve sheath meningiomas and may be associated with a risk of optic neuropathy approaching 78% at ≥ 15 Gy dose prescriptions 15 .
For fractionated radiotherapy, decades of experience have led to guidelines for normal tissue tolerance. For optic nerve and chiasm, guidelines have evolved that have proven to be extremely safe and are generally based on the optic ret dose of 890 recommended by Goldsmith 12 , later corroborated by a large retrospective analysis by Parsons 21 who also established a daily dose of 1.9 Gy as safe.
Based on the assumption that 15 Gy in a single fraction and 54 Gy in 30 fractions are biologically equivalent, the α/ß ratio for meningiomas may be calculated based on the linear quadratic formula:
Where D is the total dose, d is the dose per fraction, and α/ß is the characteristic constant associated with the particular tissue in question. Assuming BED 1 = BED 2 for tissue of an unknown α/ß:
For meningiomas using the assumption of equivalent BED for It has been clearly established that the radiation tolerance to the optic nerves and chiasm depends on the total dose of radiation and the dose per fraction. Goldsmith et. al. 12 proposed a model predicting the total dose associated with a low risk of optic neuropathy when various doses per fraction were prescribed:
Optic ret dose = Dose (cGy)/ N 0.53== Shrieve et. al. applied these formulas to the treatment of parasellar meningiomas where the optic apparatus is a dose-limiting structure 23 . If the optic ret tolerance of 890 is observed and the α/ß is assumed to be 3.28 ± 10%, a range of doses from a minimum of 46 Gy in a minimum of 22 fractions to 54 Gy in 30 fractions is necessary to achieve tumor control and an acceptable rate of optic neuropathy.
An assumption in this analysis is that vision is intact at the inception of treatment.
The natural history of primary optic nerve sheath meningiomas or meningiomas that encroach upon the optic apparatus reflects progressive visual loss to blindness in the affected eye. Assumptions regarding the morbidity of radiation treatment must in these cases be weighed against the morbidity associated with the natural history of the disease. If radiation optic neuropathy, for example, occurred at rates of 5-10% in a me- dian range of 4-6 years, and the natural history reflected rates of visual loss to blindness at 80-90% over a broader median range of 6-10 years, the therapeutic benefit would outweigh the treatment-related morbidity, even if as high as a 10% rate of optic neuropathy.
teChnique
We commissioned the world's first installation of a linear accelerator designed for and dedicated to stereotactic radiosurgery and fractionated stereotactic radiotherapy in 1994 8 . Since then, we adopted a treatment technique which incorporates stereotactic technique with conventional daily doses of radiation 2, 3, 4, 6, 7, 13, 20 . These dose-fraction protocols are designed to optimize therapeutic effect while minimizing treatment-related morbidities. Our rationale for a conventional fraction FSR paradigm stems from our belief that special sensory cranial nerves, notably the optic nerves and the cochlear nerves, are more sensitive to any therapeutic intervention including radiation therapy. Drawing from previously reported observations documenting injury thresholds for the optic nerves after radiation for head and neck cancers 21 , we have adopted a 1.8 Gy daily fraction schedule, and for most lesions, we have achieved high tumor control rates and cranial nerve preservation rates with cumulative doses ranging from 50.4 to 54 Gy (see Table 1 below). As one exception, we have achieved high tumor control rates with acoustic neuromas but still document loss of serviceable hearing after treatment. We have therefore adopted a policy of a 10% dose de-escalation every three years, attempting to seek the lowest dose yielding the highest hearing preservation rate while maintaining high tumor control rates. Details of our experiences with different intracranial targets are discussed in the following section.
Pre-treatment patient preparation involves the customized design of a lightweight relocatable frame based on either an upper arch Reprosil dental mold (Gill-Thomas-Cosman frame 11 ) or a thermoplast mask of the face. Either template is adapted to the frame and yields a reproduceable and accurate frame relocation each time it is applied for treatment. On this day both MRI and CT data are obtained. Contrast-enhanced CT data are obtained in the frame with a fiducial cage attached. The patient is removed from the frame and a gadolinium enhanced MR scan is obtained next. Both imaging datasets are electronically transferred to the treatment planning workstation where they are fused into one composite image for treatment planning purposes. Due to the high spatial fidelity of CT data, the CT dataset is an obligatory imaging dataset for treatment planning. The patient is discharged home and returns for treatment inception usually a week to 10 days later.
The Novalis treatment-planning workstation provides a number of planning options ranging from dynamic arc treatment 24 , to conformal static arcs or stereotactic IMRT. At our institution, most treatment plans involve a single isocenter treatment with five non-coplanar arcs utilizing the dynamic arc method. With mini-multileaf collimation, this technique allows for both high target conformality and high dose homogeneity, variables commonly considered to yield the highest therapeutic index. More complex skull base lesions are treated with either conformal arc or, if highly irregular concave surfaces are involved, stereotactic IMRT. Treatment planning is highly effective and efficient due to the software design which is capable of parallel treatment plans for comparison. Table 1 summarizes current dose fractionation protocols at the Jefferson Hospital for Neuroscience. 
CliniCal outComes
We have treated 126 patients to date with either primary (N = 32) or secondary (N = 94) optic nerve sheath meningiomas. Patients with unambiguous visual status and follow-up visual data identified by chart review are designated in Table 4 below. Nine patients are either at early follow-up or their ophthalmologic data are either incomplete or missing, and 29 patients have either normal vision, light perception only, or no light perception, leaving 88 patients with serviceable but compromised vision eligible for assessment of visual outcome after FSR treatment, including 18 primary ONSM and 71 patients with secondary ONSM. We initiated FSR in the early 1990s with the belief that, for selected intracranial targets, a conventional fraction FSR technique would yield higher cranial nerve preservation rates due to a greater radiobiological advantage 3, 7, 13 . This was thought to be particularly true for special sensory cranial nerves, and the most compelling example to date is the treatment of optic nerve sheath meningiomas (ONSM). Historically ONSM was either observed or first treated surgically and then observed, and in all cases patients lost vision ineluctably to blindness in the affected eye. In the modern MR era, there is no longer any surgical indication to establish a diagnosis since primary ONSM has a classic axial tram-track appearance or coronal bull target appearance in fat-suppressed gadolinium-enhanced MRI scans. Traditional radiation achieved tumor control and stabilization of vision but associated morbidities including hypopituitarism, contralateral visual loss from radiation-induced optic neuropathy, or loss of cognitive function represented too high a dose to the optic nerve in a single fraction; it is associated with a high risk of visual loss from radiation injury and is therefore not practiced.
pRImARy opTIC NERvE ShEATh mENINgIomAS
We initiated conventional fraction FSR in 1995 after we commissioned the first Varian 600SR, and taking advantage of our strong affiliation with Wills Eye Hospital, addressed a large population of patients with ONSM. Based on the data published by Parsons et. al. 21 , we initiated a dose fraction FSR program of 1.8 Gy daily fractions to a cumulative dose of 54 Gy (Table 1) and published our initial results involving 33 optic nerves in 30 patients in 2002
2 . These data reflected a 90% actuarial visual preservation rate. Two patients lost vision after treatment both of which were scored as treatment related morbidities despite lack of adequate follow-up data to determine whether visual loss was actually related to treatment failure. Both are lost to follow-up. Our current results reflect durable improvement in vision at a median follow-up of 247 weeks (range 15 to 490 weeks) (Figure 3a ) with one reported case of radiation-induced optic neuropathy (Figure 3b ) in 18 patients with serviceable vision. Sixteen of 18 patients experienced visual improvement. The actuarial rate of visual improvement (13 with compromised fields, 4 with diminished acuity, and 1 with diplopia) was 96% (Figure 3 ) below, and the median time to visual improvement was 21 weeks. Visual loss was noted in only one patient at 82 weeks, and this was ascribed to treatment. Treatment options for secondary ONSM include surgical removal and radiation. Based on our experience and literature review, the only radiation technique which yields the greatest therapeutic benefit is FSR. Surgical series have described excellent treatment outcomes with visual recovery, particularly when the optic nerve is decompressed at the orbital apex. We have treated 94 patients with secondary ONSM, 71 of whom had serviceable but compromised vision before FSR treatment. 47 of these patients had evaluable follow-up visual data. Our current results reflect durable improvement in vision at a median follow-up of 286 weeks (range 54 to 576 weeks) (Figure 4a ) with three cases of radiation-induced optic neuropathy (Figure 4b ). Thirty-one of 47 patients experienced visual improvement. As with primary ONSM, the actuarial rate of visual improvement was 96% (Figure 4a) below, but the median time to visual improvement was more than twice as long at 52 weeks. Visual loss was noted in three patients at 6 months, 11 months, and 60 months. In the lattermost case, this patient had undergone cranial irradiation as a child for lymphoma and this patient was at an increased risk of visual loss after FSR treatment of a clinoidal meningioma.
We have noted rapid improvement in visual fields for the majority of ONSM we have treated, but serial post-treatment MRI scans do not reveal change in lesion volume, particularly for primary ONSM. We have postulated that the visual improvement is a function of improved circulation to the optic nerve. A recent case report documented rapid disappearance of optociliary shunt vessels after FSR. The noteworthy feature of the case of this patient was that the shrinkage of the optociliary shunt vessels was immediate and occurred without any apparent change in the size of the tumor 9 . Radiation treatment seems to work by relaxing the compression of the optic nerve, even without obvious radiologic evidence of tumor shrinkage. Reduction in tumor compression presumably allows increased blood flow through the central retinal vein, lessening the driving force for blood flow through the optociliary collateral vessels 9 . It also accounts for the rapid improvement in optic disc edema and partial recovery of optic nerve function.
Despite these promising results, our initial experience was based on the use of circular collimators, and given the linear shape of ONSM, necessarily involved multiple overlapping isocenters. This created dose inhomogeneity along the axis of the optic nerve without apparent consequence at daily fractions of 1.8 Gy and no excessive incidence of radiation optic neuropathy was observed. With the advent of the Novalis unit, we have since adopted treatments based on a single isocenter which are much more efficient and which yield much higher dose homogeneity along the axis of the optic nerve with dynamic arc technique (Figure 1 ).
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